The Administrative Core (Core A) has fulfilled three major functions during the current grant, and will continue to do so in this renewal. One function is the overall management of the P01, which is the responsibility of the PI, Steven Balk, with an administrator and in consultation with the other PIs. This includes addressing all administrative issues, organizing group meetings, organizing internal and external reviews, and in general facilitating communications and collaborations. The second function of the Core has been to assist the Projects in efforts to ensure that their laboratory studies and findings are physiologically significant, and ultimately to translate their findings into patients. This has been facilitated by close interactions with our clinicians, represented by our internal advisory board. Through previous/ongoing clinical trials and tissue banking efforts at their respective institutions, these clinical investigators have collected (and continue to collect) valuable samples from patients at varying stages of their disease and after varying therapies. In discussions with the Project Leaders, they have provided relevant clinical samples for analysis and have provided further insight into potential biological significance of laboratory findings. The third Core function is to provide statistical support for each of the Project Leaders in their experimental designs.
The Specific Aims are 1) Provide administrative support to insure that the goals of the project are achieved, 2) Assist in translating the results from each Project into the clinic, 3) Provide biostatistical support for each Project.
The Administrative Core (Core A) is responsible for the overall management of the P01, including addressing all administrative issues, organizing group meetings, organizing internal and external reviews, and in general facilitating communications and collaborations. The second function of the Core is to assist the Projects in efforts to ensure that their laboratory studies and findings are physiologically significant, and ultimately to translate their findings into patients. The third Core function is to provide statistical support for each of the Project Leaders in their experimental designs.
|Beshiri, Michael L; Tice, Caitlin M; Tran, Crystal et al. (2018) A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening. Clin Cancer Res 24:4332-4345|
|Russo, Joshua W; Liu, Xiaming; Ye, Huihui et al. (2018) Phosphorylation of androgen receptor serine 81 is associated with its reactivation in castration-resistant prostate cancer. Cancer Lett 438:97-104|
|Mostaghel, Elahe A (2018) Alternative Acts: Oncogenic Splicing of Steroidogenic Enzymes in Prostate Cancer. Clin Cancer Res :|
|Uo, Takuma; Plymate, Stephen R; Sprenger, Cynthia C (2018) The potential of AR-V7 as a therapeutic target. Expert Opin Ther Targets 22:201-216|
|Arai, Seiji; Jonas, Oliver; Whitman, Matthew A et al. (2018) Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis. Clin Cancer Res 24:5458-5470|
|Viswanathan, Srinivas R; Ha, Gavin; Hoff, Andreas M et al. (2018) Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing. Cell 174:433-447.e19|
|Russo, Joshua W; Gao, Ce; Bhasin, Swati S et al. (2018) Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer. Cancer Res 78:6354-6362|
|Sowalsky, Adam G; Ye, Huihui; Bhasin, Manoj et al. (2018) Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations. Cancer Res 78:4716-4730|
|Zhu, Yezi; Sharp, Adam; Anderson, Courtney M et al. (2018) Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer. Eur Urol 73:727-735|
|Penning, Trevor M (2018) Dehydroepiandrosterone (DHEA)-SO4 Depot and Castration-Resistant Prostate Cancer. Vitam Horm 108:309-331|
Showing the most recent 10 out of 90 publications